Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.37 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in late spermatids | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0741
Sealed predictions
- CCDC88A in dopamine neurons, braak+0.39 (p 0.306) → -0.22 (p 0.565)receipt 0748
- CCDC88A in oligodendrocytes, braak+0.18 (p 0.644) → -0.03 (p 0.946)receipt 0747
Swarm cases
receipt 0748: CCDC88A in dopamine neurons, braak
- power
- full sample +0.05 (p 0.854, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.07 (p 0.774, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.18, sign flips 4; without severely affected donors +0.05 (p 0.854, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCDC88A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0747: CCDC88A in oligodendrocytes, braak
- power
- full sample +0.16 (p 0.532, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.696, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.18 (p 0.487, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.31, sign flips 0; without severely affected donors +0.16 (p 0.532, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCDC88A in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts